22nd Century Group ( ) - 株価, ニュースと分析Nasdaq:XXII

XXII 株式概要

タバコ製品会社である22nd Century Group, Inc.は、独自の新型ニコチン低減タバコ製品の販売・流通に従事している。詳細

XXII ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

リスク分析

過去1年間で株主の希薄化は大幅に進んだ

意味のある時価総額がありません ( $5M )

過去3か月間の株価の変動は非常に激しい

過去5年間で収益は年間19.7%減少しました。

22nd Century Group, Inc. 競合他社

VPR Brands

OTCPK:VPRB

US$3.9m

Charlie's Holdings

OTCPK:CHUC

US$22.5m

Pyxus International

OTCPK:PYYX

US$61.8m

Tofutti Brands

OTCPK:TOFB

US$3.9m

価格と性能

の歴代最高値、変動、値下がりまとめ22nd Century Group
過去の株価
現在の株価	US$0.094
52週高値	US$5.28
52週安値	US$0.083
ベータ	1.45
11ヶ月の変化	-22.87%
3ヶ月変化	-81.44%
1年変化	-97.39%
33年間の変化	-99.98%
5年間の変化	-99.96%
IPOからの変化	-99.97%

Recent updates

Market Participants Recognise 22nd Century Group, Inc.'s (NASDAQ:XXII) Revenues Pushing Shares 1,233% Higher

Apr 02

Time To Worry? Analysts Just Downgraded Their 22nd Century Group, Inc. (NASDAQ:XXII) Outlook

Aug 20

With 22nd Century Group, Inc. (NASDAQ:XXII) It Looks Like You'll Get What You Pay For

Jun 14

Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Jan 13

22nd Century adds Creager as distribution partner for its VLN cigarettes in Colorado

Oct 03

株主還元

	XXII	US Tobacco	US 市場
7D	2.2%	4.6%	2.2%
1Y	-97.4%	-5.7%	31.7%

業界別リターン: XXII過去 1 年間で-5.7 % の収益を上げたUS Tobacco業界を下回りました。

リターン対市場: XXIIは、過去 1 年間で31.7 % のリターンを上げたUS市場を下回りました。

価格変動

Is XXII's price volatile compared to industry and market?
XXII volatility
XXII Average Weekly Movement	19.5%
Tobacco Industry Average Movement	7.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

安定した株価: XXIIの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: XXIIの週次ボラティリティは過去 1 年間で26%から20%に減少しましたが、依然としてUS株の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
1998	64	Larry Firestone	www.xxiicentury.com

タバコ製品会社である22ndセンチュリー・グループ社は、独自に開発した新しい減ニコチン・タバコ製品の販売・流通に従事している。同社はニコチン含有量を減らしたタバコ工場と超低ニコチン可燃性タバコ製品を提供している。また、他社ブランド向けに従来型可燃性タバコ製品の受託製造サービスも提供している。同社は1998年に設立され、ノースカロライナ州モックスビルに本社を置いている。

22nd Century Group, Inc. 基礎のまとめ

22nd Century Group の収益と売上を時価総額と比較するとどうか。
XXII 基礎統計学
時価総額	US$4.59m
収益（TTM）	-US$50.09m
売上高(TTM)	US$17.30m

0.3x

P/Sレシオ

-0.1x

PER（株価収益率

XXII は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
XXII 損益計算書（TTM）
収益	US$17.30m
売上原価	US$26.28m
売上総利益	-US$8.98m
その他の費用	US$41.11m
収益	-US$50.09m

直近の収益報告

Sep 30, 2024

次回決算日

該当なし

一株当たり利益（EPS）	-1.08
グロス・マージン	-51.87%
純利益率	-289.46%
有利子負債／自己資本比率	218.8%

XXII の長期的なパフォーマンスは？

過去の実績と比較を見る

XXII 株式概要

リスク分析

22nd Century Group, Inc. 競合他社

OTCPK:VPRB

US$3.9m

OTCPK:CHUC

US$22.5m

OTCPK:PYYX

US$61.8m

OTCPK:TOFB

US$3.9m

価格と性能

最新ニュース

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.27 loss per share (vs US$58.96 loss in 3Q 2023)

22nd Century Group, Inc. announced that it expects to receive $3.039363 million in funding

22nd Century Regains Compliance with Nasdaq Stockholders’ Equity Requirement

New major risk - Share price stability

22nd Century Group, Inc. announced that it expects to receive $1.6815 million in funding

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.27 loss per share (vs US$58.96 loss in 3Q 2023)

22nd Century Group, Inc. announced that it expects to receive $3.039363 million in funding

22nd Century Regains Compliance with Nasdaq Stockholders’ Equity Requirement

New major risk - Share price stability

22nd Century Group, Inc. announced that it expects to receive $1.6815 million in funding

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$22.45 loss in 2Q 2023)

22nd Century Group, Inc. to Report Q2, 2024 Results on Aug 13, 2024

22nd Century Group, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

22Nd Century Group, Inc. Appoints Robert Manfredonia as Executive Vice President of Sales and Marketing, Effective from August 1, 2024

22nd Century Group, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

22nd Century Group, Inc. to Report Q1, 2024 Results on May 15, 2024

22nd Century Group, Inc., Annual General Meeting, Jun 28, 2024

22nd Century Group, Inc. announced that it has received $4.2 million in funding

22nd Century Group, Inc. has filed a Follow-on Equity Offering in the amount of $4.237199 million.

22nd Century Group Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Nasdaq's Listing Rule 5550(b)(1)

Market Participants Recognise 22nd Century Group, Inc.'s (NASDAQ:XXII) Revenues Pushing Shares 1,233% Higher

New major risk - Share price stability

No longer forecast to breakeven

Full year 2023 earnings released: US$3.12 loss per share (vs US$4.65 loss in FY 2022)

22nd Century Group, Inc. to Report Q4, 2023 Results on Mar 28, 2024

22Nd Century Group, Inc. Announces Termination of Peter Ferola as the Chief Legal Officer and Corporate Secretary

High number of new directors

22Nd Century Group, Inc. Appoints Lawrence (Larry) Firestone as Chief Executive Officer

Specialty Acquisition Corporation entered into a equity purchase agreement to acquire Substantially all of GVB hemp/cannabis business from 22nd Century Group, Inc. (NasdaqCM:XXII) and ESI Holdings, LLC for $2.3 million.

Consensus EPS estimates fall by 67%

New major risk - Market cap size

22nd Century Group Receives Non-Compliance Letter from Nasdaq

22nd Century Group, Inc. Continues VLN Expansion, Now Retailing in More Than 5,100 Stores

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Shareholder dilution

22Nd Century Group, Inc. Adds 1,200 Drug Store Locations Selling VLN in Five States

Consensus revenue estimates fall by 11%

Time To Worry? Analysts Just Downgraded Their 22nd Century Group, Inc. (NASDAQ:XXII) Outlook

Price target decreased by 27% to US$31.19

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

22nd Century Group, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Pomerantz LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of 22nd Century Group, Inc. Common Stock

High number of new directors

22Nd Century Group, Inc. Announces Chief Executive Officer Changes

22nd Century Group Regains Compliance with Nasdaq Listing Standards

22Nd Century Group, Inc. Announces Its Vln(R) Reduced Nicotine Content C-Stores

New minor risk - Share price stability

22nd Century Announces 1-For-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

22nd Century Group, Inc. Announces Production of VLN(R) Homogenized Tobacco Leaf Sheet

22nd Century Group, Inc. Announces VLN(R) Products Launch in Nevada to Help Smokers Smoke Less

With 22nd Century Group, Inc. (NASDAQ:XXII) It Looks Like You'll Get What You Pay For

22Nd Century Group, Inc. Launches Vln At #1 U.S. C-Store Chain in Texas, California and Florida

Consensus revenue estimates increase by 10%, EPS downgraded

22nd Century Group, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 11% to US$4.00

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

22nd Century Group, Inc. to Report Q1, 2023 Results on May 09, 2023

Consensus EPS estimates fall by 16%

Full year 2022 earnings: EPS and revenues miss analyst expectations

22nd Century Group, Inc. (NasdaqCM:XXII) acquired Rx Pharmatech Ltd for $0.65 million.